# Evaluation of Safety, Tolerance, and Efficacy of Allogeneic LB-DTK-COV19 in Severe Coronavirus Disease 2019 Patients

> **NCT07709637** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **LucasBio** · enrollment: 1 (actual)

## Conditions studied

- COVID-19
- COVID-19 (SARS-CoV-2 Infection)

## Interventions

- **BIOLOGICAL:** LB-DTK-COV19

## Key facts

- **NCT ID:** NCT07709637
- **Lead sponsor:** LucasBio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-07-31
- **Primary completion:** 2026-10-31
- **Final completion:** 2026-10-31
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2026-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07709637

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07709637, "Evaluation of Safety, Tolerance, and Efficacy of Allogeneic LB-DTK-COV19 in Severe Coronavirus Disease 2019 Patients". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07709637. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*